SCHEMBL260479

SCHEMBL260479

Nc1ccc(CN2N=C(c3ccc(Cl)cc3)COC2=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GRM2 Q14416 1/20 0.38
PGR P06401 1/20 0.37
LMNA P02545 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
PRKCZ Q05513 1/20 0.36
TSHR P16473 1/20 0.36
HPGD P15428 1/20 0.36
MAOA P21397 2/20 0.36
MAOB P27338 1/20 0.36
NOTUM Q6P988 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260488 0.83 MAPT (0.49) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL6964280 0.80 PDE4B (0.54)
SCHEMBL260681 0.78 LMNA (0.63) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL259729 0.78 AHR (0.45) PGRMAOB
SCHEMBL665129 0.75 GRM2 (0.36) MAPTTP53SMN1; SMN2KDM4EGRM2
SCHEMBL2085735 0.66 LMNA (0.63) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL631741 0.62 GFER (0.74) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL261421 0.62 ALDH1A1 (0.57) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL2772180 0.60 ALDH1A1 (0.49) GRM2ALDH1A1MAOB
SCHEMBL11281290 0.60 TSHR (0.52) MAPTSMN1; SMN2MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653073-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2014-02-18 US disclosed
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2013-12-12 US disclosed
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
EP-2281822-B1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2013-01-16 EP disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed
EP-2281822-A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2011-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP11B1, SDHA, CYP11B2 MAPT 4278/4885TP53 274/4885SMN1; SMN2 2931/4885
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 MAPT 4278/4885TP53 274/4885SMN1; SMN2 2931/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 MAPT 4278/4885TP53 274/4885SMN1; SMN2 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.